Patient Case Review: Investigating Treatment Profiles, Exploring the Role of Treatment Adherence and Drug Class Selection Considerations

Obesity & Type 2 Diabetes: An Expert Discussion

Both metformin and GLP-1 RAs have been studies for their neuroprotective effects; this study is the first head-to-head investigation and supports further research.

New Guidelines Recommend Preconception Screening in Diabetes, Universal Testing for Primary Aldosteronism

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

ENDO 2025: The publications reflect growing consensus that integration of endocrine screening into standard clinical workflows is essential for early risk detection and long-term disease prevention.

Novel GLP-1/GLP-2 Agent Reduces Body Weight by Up to 8.3% in Phase 1b Obesity Trial

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD.

Once-Monthly Maridebart Cafraglutide Produces Up to 20% Weight Loss in Phase 2 Trial

ADA 2025: Dapiglutide showed promising safety and weight loss results in a phase 1b trial, targeting obesity and inflammation with once-weekly dosing.

GLP-1 RAs vs Metformin Significantly Reduce Risk of Dementia in Adults with Type 2 Diabetes

ADA 2025: Once-monthly dosing led to significant weight loss in adults with obesity, with or without type 2 diabetes, reported researchers.

Related Content

Obesity & Type 2 Diabetes: An Expert Discussion

Both metformin and GLP-1 RAs have been studies for their neuroprotective effects; this study is the first head-to-head investigation and supports further research.

New Guidelines Recommend Preconception Screening in Diabetes, Universal Testing for Primary Aldosteronism

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

ENDO 2025: The publications reflect growing consensus that integration of endocrine screening into standard clinical workflows is essential for early risk detection and long-term disease prevention.

Novel GLP-1/GLP-2 Agent Reduces Body Weight by Up to 8.3% in Phase 1b Obesity Trial

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD.

Once-Monthly Maridebart Cafraglutide Produces Up to 20% Weight Loss in Phase 2 Trial

ADA 2025: Dapiglutide showed promising safety and weight loss results in a phase 1b trial, targeting obesity and inflammation with once-weekly dosing.